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SUMMARY  The aim of our study was to analyze the results obtained with 
the ReCell system for surgical treatment of stable vitiligo. At Department of 
Plastic and Reconstructive surgery, University of Tor Vergata in Rome, we 
treated 15 patients with stable vitiligo during a 2-year period. The stability of 
vitiligo lesions varied between 1 and 4 years. The mean stability was 2.25. 
The disease activity according to Vitiligo Disease Activity Score (VIDA) 
was 0 in all cases, which means that all patients had a stability of greater 
than or equal to 1 year. Three (20%) patients had vitiligo vulgaris, seven 
(46.6%) segmental vitiligo and five (33.3%) focal vitiligo. Repigmentation 
was assessed using the Vitiligo Area Scoring Index (VASI). The extent of 
pigmentation was scored as excellent, good, fair, and poor depending on 
the percentage of repigmentation in the previously depigmented site. The 
color of the repigmented area was compared with the adjacent normally 
pigmented area: excellent color match was present in ten (66.6%) and good 
in five (33.3%) cases. There was no fair or poor outcome. Repigmentation 
greater than 75% was recorded in 12 (80%) and 25% to 50% repigmenta-
tion in three (20%) of 15 patients treated. ReCell® is a feasible, simple and 
safe technique. The method that uses noncultured autologous epidermal 
suspension is simpler, less expensive, less time consuming, and does not 
require sophisticated laboratory facilities as compared with the methods 
employing cultured melanocytes.
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INTRodUCTIoN
 Vitiligo is one of the most common acquired pig-
mentation disorders. This cosmetically disfiguring 
condition, particularly in dark-skinned individuals, 
affects 0.1%-2% of the world’s population, with an 
equal sex distribution (1). A general knowledge of 
the causes of depigmentation is particularly rele-
vant for understanding the possibilities and limita-
tions of surgery for vitiligo.
 As it is well known, vitiligo is a visible cosmet-
ic defect that leads to serious emotional stress. 
Vitiligo lesions on the exposed areas of the body, 
especially on the face, have strong impact on the 
patient’s self-esteem and social relationships.
 Treatment of vitiligo is often difficult and disap-
pointing. There are many surgical options in the 
treatment of refractory vitiligo including minigrafting, 
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micropigmentation, split-thickness skin grafting, 
suction blister transplantation, transplantation of 
cultured autologous melanocytes, keratinocyte/
melanocyte co-cultures, or noncultured suspen-
sion of epidermal cells (2).
 In the last years, several surgical therapies 
including the use of autologous skin grafts have 
been proposed. These methods can be used in 
vitiligo that is refractory to medical treatment, in 
patients with piebaldism, or to obtain repigmenta-
tion in case of thermal burns, trauma, and inflam-
mation (3). It is mandatory to treat only patients 
showing stability in their vitiligo lesions: hypopig-
mented patches should be stable for at least 2 
years before surgical therapy. This article deals 
with the ReCell® technique in the treatment of re-
fractory vitiligo.
PATIeNTS ANd MeTHodS
 The study included 15 otherwise healthy pa-
tients (six men and nine women) admitted for 
stable vitiligo to Department of Plastic and Recon-
structive Surgery, University of Tor Vergata, Rome. 
The study was approved by the Ethics Commit-
tee of the National Center for Vitiligo and Psoria-
sis. Patients were treated between January 2007 
and February 2008. The stability of vitiligo lesions 
varied between 1 and 4 years, the mean stabil-
ity 2.25 years. The disease activity according to 
Vitiligo Disease Activity Score (VIDA) was 0 in all 
cases, which means that all patients had a stabil-
ity of greater than or equal to 1 year. Three (20%) 
patients had vitiligo vulgaris, seven (46.6%) had 
segmental vitiligo and five (33.3%) had focal vitili-
go. The involved area was evaluated by use of the 
Vitiligo Area Scoring Index (VASI). One hand unit, 
which encompasses the palm plus volar surface 
of all digits, is approximately 1% of the total body 
surface area and was used as a guide to estimate 
the baseline percentage of vitiligo involvement of 
each body region. The total body VASI was then 
calculated using the following formula, consider-
ing the contributions of all body regions (possible 
range, 0-100):
VASI = ∑ [Hand Units] x [Residual Depigmentation]
 Patients were informed about the study and 
their written consent was obtained. Inclusion cri-
teria were: stable vitiligo cases having no progres-
sion of existing lesions and/or no appearance of 
new lesions in the past 1 year and with areas in-
volved less than 320 cm2. Exclusion criteria were: 
patient less than 10 years of age, extensive depig-
mented areas where grafting may not yield cos-
metically good results, concomitant serious sys-
temic disease, and keloidal/bleeding tendency.
 The following patient data were recorded for 
regular follow up: name, age, sex, occupation, 
and address. Thorough disease history was taken 
including disease duration, site of onset, progres-
sion, trichrome/multichrome sign, type of lesion, 
distribution and stability of lesion (Table 1). Medi-
cal management for vitiligo or any other disease, if 
taken, was noted.
Table 1. Demographic and clinical characteristics
Age (yrs) 18-45 (mean ) 
Sex
   male




Duration of disease (yrs) 1-4 (mean 2.25)
Positive family history
  paternal 
  maternal 






  vitiligo vulgaris
  segmental vitiligo






  forearm 
  hand 
  lower limb 






 General physical examination and systemic 
evaluation were performed to rule out any other 
concomitant dermatologic or medical disorder. 
Oral antibiotics and analgesics were administered 
until postoperative day 7. Minimal follow up period 
was 6 months.
Figure 1. Cutaneous biopsy.
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 Pretreatment and post-treatment photographs 
were taken to document the pigmentation before 
and after the surgery at the end of the first, third and 
sixth months. A square lattice grid on tracing paper 
was used for the assessment of the size of the do-
nor and transplanted areas, and the extent of the 
spread of repigmentation. Repigmentation was as-
sessed by use of VASI. Global assessments were 
made to compare the VASI system with analogous 
ordinal scales. Upon completion of the study, each 
patient and one of the authors separately graded 
the treated sides on a 6-point ordinal scale based 
on global estimate of the change in vitiligo as fol-
lows: complete improvement (100%), very much 
improved (76%-99%), much improved (51%-75%), 
improved (26%-50%), minimal change (1%-25%), 
and no change. The results were assessed by the 
plastic surgeon and the patients themselves, their 
family members and/or close friends. Cosmetic re-
sults were graded on a 4-point ordinal scale by the 
patients and the surgeon as excellent, good, fair 
and poor. 
ReCell® kit
 ReCell® is a single-use battery-operated autol-
ogous cell-harvesting device. It consists of a pro-
cessing unit with built-in heating mechanism for 
warming the enzyme solution to optimum working 
temperature (37 ºC) and a removable insert to act 
as a sterile Petri dish for use when separating and 
scraping the skin biopsy. In addition, it contains 
a sealed glass vial of enzyme, lyophilized trypsin 
0.75% (minimum activity 3000 Tu mL)1, equiva-
lent to 50 lkat mL)1), 1x10 mL ampoule of sterile 
water, 1x10 mL vial of compound sodium lactate. 
Biopsy and cell separation using 
ReCell® kit
A thin split-thickness cutaneous biopsy (0.2-0.3 
mm) was harvested from an uninvolved area us-
ing a Zimmer dermatome (Zimmer, Indiana, USA). 
According to the manufacturer’s instructions, as 
the cellular spread rate is 1:80, the biopsy area 
was 1 cm2 when the recipient area was 80 cm2 
and 4 cm2 when the recipient area was 320 cm2. 
The epidermis was put in 4.5 mL of trypsin solution 
for 20 min at 37-38 ºC to begin the intercellular de-
tachment. While the biopsy was processed, clas-
sic escharotomy was applied on eschars of vitiligo 
and deep partial thickness areas with thick fibrin 
slough. Upon completion of digestion with trypsin, 
the epidermis was separated from the dermal lay-
ers and epidermal cells were further divided with 
the scalpel blade. Cells were further suspended in 
lactate solution, aspirated several times to create 
cell suspension with a 5-mL syringe and sprayed 
over the area to be treated and the biopsy site. All 
procedures were performed in the operating room 
and under general anesthesia. In all patients, an 
adequately debrided wound bed was achieved 
with tangential escharotomy.
 Medication was administered with non-adher-
ing dressings (Adaptic, Johnson and Johnson 
Wound Management, Ethicon) and gauzes on 
both areas.
ReSULTS 
 From January 2007 to February 2008, we en-
rolled 15 patients (six men and nine women) for 
the clinical trial. Demographic and clinical charac-
teristics and outcome for both groups are summa-
rized in Table 1. Five (33.3%) patients had pater-
nal family history, three (20%) had maternal family 
history, and seven (46.6%) had no family history of 
vitiligo.
Figure 2. Separation of the epidermal layer from 
the dermis. 
Figure 3. Recipient area.
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 The involved area were forearms in two 
(13.3%), hands in five (33.3%), lower limbs in four 
(26.6%) and feet in four (26.6%) patients. Re-
pigmentation was assessed by use of VASI. The 
main parameter to measure the efficacy of treat-
ment was the percentage area of repigmentation 
in test lesions. Patients had clinical stability of 3, 5 
and 1 year. Out of 15 study patients, greater than 
75% repigmentation was achieved in 12 (80%) 
and 25%-50% repigmentation in three (20%) pa-
tients, whereas no repigmentation at all was not 
recorded in any of the study patients. The cos-
metic result was scored as excellent, good, fair, 
or poor by the surgeon and the patients. The color 
of the repigmented area was compared with the 
adjacent normally pigmented area; excellent color 
match was present in ten (66.6%) and good in five 
(33.3%) cases. There was no fair or poor outcome. 
The data collected were analyzed and are shown 
in Table 2. The time to repigmentation was three 
weeks in six (40%) and five weeks in nine (60%) 
patients. There were no serious complications like 
pain or infection, either at biopsy site or in the in-
volved area. The patient subjective global assess-
ment showed that ten (66.6%) patients were very 
satisfied and five (33.3%) were satisfied. None of 
the patients reported being unsatisfied with the 
cosmetic result.
dISCUSSIoN
 The skin contains a number of different cell 
types (4). Keratinocytes are the most common cell 
type in the epidermis and form the surface barrier 
layer. Melanocytes are found in the lower layer of 
the epidermis and provide skin color. Prolifera-
tion, differentiation and migration of melanocytes 
and melanoblasts are regulated by keratinocyte-
derived factors and some coat color genes (5). 
Keratinocytes synthesize and secrete a wide va-
riety of cytokines. As its well known, cytokines 
provide the cell-to-cell communication system be-
tween adjacent cells (paracrine effect), between 
cells at distant sites (endocrine effect), and inter-
cellular effects (autocrine effect).
 Any therapy for vitiligo must explain not only 
the repopulation of melanocytes but also their 
functional development. Vitiligo is an acquired 
pigmentary disorder characterized by depigmen-
tation of the skin and hair. As the pathogenesis of 
the disease is still obscure, the treatment of vitiligo 
has generally been unsatisfactory and often dis-
appointing.
 Topical therapies like steroids, psoralen, tacro-
limus, placental extract, and systemic steroids are 
commonly used in daily clinical practice. These 
diverse medical therapies have been shown to 
produce satisfactory repigmentation in only 50% 
of cases, especially in limited extent vitiligo, and 
because of their simplicity, they might be consid-
ered as a reasonable first step in the treatment of 
vitiligo (6), reserving more complex surgical meth-
ods (including tattooing, etc.) when resistant forms 
of vitiligo are encountered (7).
 Surgical treatment options for vitiligo offer the 
potential for rapid and more desirable amounts of 
repigmentation. The different modalities of surgical 
techniques include tattooing, organ-cultured fetal 
skin allografting, epidermal culture grafting, me-
lanocyte culture grafting, autologous noncultured 
melanocyte-keratinocyte cell transplantation, epi-
dermal grafting by the suction blister technique, 
thin Thiersch split skin grafting, or miniature punch 
grafting. Treatment of vitiligo is very complex. It is 
Table 2. Functional and cosmetic outcome
Outcome  n (%)
Extent of repigmentation (%)
  100
  76-99
  51-75 
























Figure 4. Preoperative view.
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well recognized that the response varies accord-
ing to the anatomic location of the lesion. Vitiligi-
nous lesions localized in the dorsum of the hands, 
distal sections of limbs, genitals, around the mouth 
and nipples are characterized by poor response to 
conservative therapy (pharmacological therapy, 
phototherapy, photochemotherapy, immunother-
apy) (8). It is possible to achieve repigmentation 
using surgical treatment based on the transfer of 
autologous melanocytes to the vitiliginous lesions 
(2).
 Most tissue-engineered skin is created by ex-
panding skin cells in the laboratory (at a rate much 
greater than would be achieved in the patient) and 
using them to restore barrier function (the prima-
ry objective in burn patients) or to initiate wound 
healing (in chronic non-healing ulcers) (4). Other 
uses include accelerating healing, reducing pain 
in superficial burns and correcting conditions in 
which healing has been suboptimal (for example, 
in scars, contractures or pigmentary defects). 
 Since 1987, there have been many reports on 
transplantation of cultured autologous melano-
cytes (9,10). As it involves in vitro multiplication 
of cells, the use of various culture media is obliga-
tory. Culture techniques require a state-of-the-art 
laboratory, highly trained staff and at least two 
visits by the patient, and are quite expensive. As 
such, they are restricted to very specialized cen-
ters and are mainly useful for research purposes. 
Subsequently, the culture technique was modified 
by eliminating the step of in vitro culture of mela-
nocytes, and cells were transplanted directly onto 
the affected depigmented area (11). The use of the 
ReCell® device for harvesting and preparing cells 
for seeding produced consistent cell counts with 
a high viability. In addition, the isolation of the cell 
population directly from the DEJ provides a source 
of cells with no selection, as would be expected 
during culturing, and contains not only basal layer 
keratinocytes but also melanocytes, papillary der-
mal fibroblasts and Langerhans giant cells. This 
may enhance the final outcome, with the presence 
of melanocytes enhancing repigmentation of the 
wound. The use of sodium lactate as a cell sus-
pension medium was first initiated by Clinical Cell 
Culture for ReCell® (12). This device was devel-
oped to treat superficial burn injuries with the help 
of epidermal cell transplantation (12,13). During 
the management of superficial burn by ReCell® it 
was observed that the resultant healing was ac-
companied by a satisfactory repigmentation. This 
led to the use of this device in the treatment of 
stable vitiligo maculae. In our study, we treated 15 
patients with stable vitiligo. Repigmentation was 
assessed using VASI. We performed global as-
sessment to compare the VASI system with anal-
ogous ordinal scales. Out of 15 study patients, 
greater than 75% repigmentation was achieved in 
12 (80%) and 10%-50% repigmentation in three 
(20%) patients, whereas none of the patients 
had no repigmentation at all. The patient subjec-
tive global assessment showed 66% of them to 
be very satisfied and 33% satisfied. Ours results 
proved the efficacy of ReCell for the treatment of 
vitiligo. However, based on the currently available 
literature, it is difficult to compare the efficacy of 
different treatment modalities not only because 
the measurement of repigmentation is not stan-
dardized, but also because most of the published 
studies were uncontrolled by design.
CoNCLUSIoN
 In recent years, several molecules such as leu-
kotriene C4, transforming growth factor, 50 basic 
fibroblast growth factor, stem cell factor and en-
dothelin 151 have been shown to stimulate pig-
ment cell migration in vitro (14). If similar and/or 
more potent molecules are identified, it is conceiv-
able that when applied to the vitiliginous skin, they 
could stimulate continuous melanocyte migration 
from the edge of the lesion and/or hair follicle res-
ervoir towards the depigmented skin for repigmen-
tation of extensive vitiligo areas.
 Tissue-engineered skin has delivered consid-
erable benefits to patients with burns and chronic 
wounds, and has enormous potential that is only 
just beginning to be realized.
Figure 5. Postoperative view at 2 years without 
sun exposure. 
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 The method that uses noncultured autologous 
epidermal suspension is simpler, less expensive, 
less time consuming, and does not require sophis-
ticated laboratory facilities, when compared with 
the methods employing cultured melanocytes; 
however, limitations still exist: the surface areas 
that can be covered using the noncultured method 
are smaller than those which can be treated with 
cultured melanocyte grafting (15).
In conclusion, ReCell® may be an effective method 
to treat vitiligo. Studies on larger series of patients 
are required to confirm its efficacy.
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